GLP-1 Weight Loss: What to Expect in Your First 6 Months

Most GLP-1 programs start at a low dose and titrate up over several weeks or months. During the first month, you're typically on a fraction of the target maintenance dose.

Weight loss in month one is usually modest—most people lose 2–5 pounds. The bigger change is often a reduction in appetite and food cravings, which many people notice almost immediately.

Side effects are also most common in the first month. Nausea, mild fatigue, and digestive changes are typical as your body adjusts to the medication.

By months 2 and 3, most patients have moved to a higher dose and are beginning to see more meaningful weight loss. Average weekly loss often increases to 0.5–1 pound per week during this phase.

Side effects typically subside for most people as the body adapts. Appetite suppression tends to become more consistent, making dietary changes easier to sustain.

This is also when some patients plateau briefly as their body adjusts to a new dose. Patience through these periods matters—the next dose increase usually restarts progress.

By month 4–6, many patients reach or approach their target maintenance dose. Weight loss continues but the rate often slows somewhat as the body adapts.

By the 6-month mark, most clinical studies show patients have lost 8–12% of their starting body weight on semaglutide. Those on tirzepatide often show higher numbers—12–16% at the 6-month mark in some studies.

This is a meaningful point to assess: how you're responding, whether the current dose is appropriate, and whether any adjustments to lifestyle habits could improve outcomes.

Not everyone responds identically to GLP-1 medications. Several factors influence individual results, including starting weight, metabolic health, adherence to the dosing schedule, and dietary habits during treatment.

Research consistently shows that patients who make dietary improvements alongside GLP-1 use lose more weight than those who rely on the medication alone. The appetite-suppressing effects make eating less easier, but food quality still matters.

Sleep quality and stress levels also play a role. GLP-1 medications work within your broader metabolic environment, and factors like poor sleep or high cortisol can slow progress.

Head-to-head, tirzepatide has shown greater average weight loss than semaglutide in clinical comparisons. The SURMOUNT-5 trial showed tirzepatide users losing approximately 20% of body weight vs 14% for semaglutide users over 72 weeks.

However, both produce clinically meaningful results that significantly exceed what's achievable through lifestyle changes alone.

The best medication is the one you can access affordably and take consistently. A slightly less effective medication taken regularly will outperform a more effective one taken inconsistently due to cost or side effects.

Clinical evidence is consistent: a significant portion of weight lost on GLP-1 medications returns when the medication is discontinued. GLP-1 mechanisms reduce appetite as long as the drug is active, but the underlying biology reasserts itself when it's stopped.

This doesn't mean the medication has failed—it reflects the chronic nature of obesity. Many healthcare providers now view GLP-1 therapy as a long-term intervention rather than a short-term fix.

Understanding this upfront helps set realistic expectations and informs decisions about treatment duration, cost planning, and the role of lifestyle changes in sustaining results.